预约演示

'Unprecedented' demand for Eli Lilly's Zepbound sparks US supply constraints

2024-03-29

Eli Lilly's new obesity med Zepbound has been on the market for less than six months and is in high demand nationwide.

ElieLillyn, a meobesityin thZepboundr GLP-1 class of diabetes and weight loss therapies is facing supply hurdles.

This time, the drug that pharmacies caGLP-1onsistentldiabetesn shelves is Eli Lilly's GIP/GLP-1 obesity offering Zepbound, thanks to what the company describes as "unprecedented" demand.

While the weight loss shot is not currently listed on the FDA’s shortage lEli,Lillymacies across the nation are sZepboundg to keep the drug on shelves, Bloomberg News reports.

For example, Amazon Pharmacy, a third-party dispensing proFDAer for Lilly, lists four out of six dosage strengths as “unavailable."

The online phAmazon Pharmacyorts that Lilly’s diabetes injection MouLilly (tirzepatide) is unavailable. The drug shares the same active ingredient as Zepbound.

“While Lilly continues to manufacture Lillyhipdiabeteses of ZepboMounjaro ttirzepatidecedented demand for these medicines, some patients may experiencZepboundulty when trying to fill their prescription at their pharmacy,” a Lilly spokesperson told Fierce Pharma in an emailed statement.

PatientLillyse treatment regimens are disrupted can try nearZepboundacies and reach out to healthcare providers if they experience continued disruptions, Lilly's spokesperson said.Lilly

The drugmaker is “moving with purpose and urgency to ensure our innovations are available to those who need them,” the spokesperson added.Lilly

At Rite Aid, a spokesperson said high demand for Zepbound has “created some sporadic supply constraints." Walgreens, too “continues to work with supplier and distribution partners to help meet patient demand,” a company representative told Fierce Pharma.

As Rite Aidjaro, the FDA has acknowledged an ongoZepboundtage. Certain doses are expected to be in short sWalgreensil the end of the month.

While bMounjaroepbounFDAnd Mounjaro may be in short supply, fraudulent copycats are reportedly swarming the market.

Earlier in MarZepboundy aleMounjaroients to the safety risks of using compounded or counterfeit versions of tirzapatide, which it has found often contain bacteria and high impurity levels. The company reiterated its commitment to pursuing legal action against those who falsely claim the Mounjaro or Zepbound name, including “certain medical spas, wellness centers, and compounding pharmacies.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构